Durect looks ahead to liver indications after Phase IIa miss in psoriasis

Although the failure of topical DUR-928 in a Phase IIa psoriasis trial vaporized more than a quarter of Durect’s market cap on Thursday, the company is pressing on

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE